Patrick I. Borgen, MD, Discusses Upcoming Breast Cancer Conferences

Video

The breast cancer expert discussed the importance of attending breast cancer meetings like the San Antonio Breast Cancer Symposium and the Miami Breast Cancer Conference.

Patrick I. Borgen, MD, chair of surgery and director of the Breast Cancer Program at Maimonides Medical Center, discussed the importance of attending breast cancer meetings like the San Antonio Breast Cancer Symposium and the Miami Breast Cancer Conference.

Transcription:

In December of this year, we will once again enjoy the San Antonio Breast Cancer Symposium. This is a very long running scientific meeting where a number of the seminal research discoveries over the years have been presented. And while we’re not supposed to really know what is coming out, I think that there are some very important clinical trials that are going to be unblinded and talked about. There are going to be some emerging agents that will play a bigger role. So, we are all very excited about San Antonio this year.

 

I will mention that while San Antonio shares where things are, it doesn’t really address how to apply them practically and I think that is where the Miami Breast Cancer Conference comes in to take the scientific knowledge from San Antonio and apply it practically. How do I take all of this information and apply it to the patient in front of me. And I think that is what Miami does.  

Recent Videos
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.
Patients with HR-positive, HER2-positive breast cancer and high-risk features may derive benefit from ovarian function suppression plus endocrine therapy.
Paolo Tarantino, MD discusses updated breast cancer trial findings presented at ESMO 2024 supporting the use of agents such as T-DXd and ribociclib.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Related Content